[(1R,5S,6r)-3-benzyl-3-azabicyclo[3.1.0]hex-6-yl]methanol hydrochloride | 1422130-51-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: [(1R,5S,6r)-3-benzyl-3-azabicyclo[3.1.0]hex-6-yl]methanol hydrochloride
• CAS: 1422130-51-5
• 化学式: C₁₃H₁₇NO*ClH
• 分子量: 239.745
• InChiKey: DUVUBGYDQYULPY-LUNMCBQDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.78
• 重原子数：
  16.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  23.47
• 氢给体数：
  1.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  [(1R,5S,6r)-3-benzyl-3-azabicyclo[3.1.0]hex-6-yl]methanol hydrochloride 在 氯化亚砜 、 硫酸 、 10% palladium hydroxide on charcoal 、 氢气 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 80.0 ℃ 、344.75 kPa 条件下， 反应 81.25h， 生成 (1α,5α,6α)-(3-aza-bicyclo[3.1.0]hex-6-yl)-acetic acid ethyl ester
  参考文献：
  名称：

  Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose

  摘要：

  Increased fructose consumption and its subsequent metabolism have been implicated in metabolic disorders such as nonalcoholic fatty liver disease and steatohepatitis (NAFLD/NASH) and insulin resistance. Ketohexokinase (KHK) converts fructose to fructose-1-phosphate (F1P) in the first step of the metabolic cascade. Herein we report the discovery of a first-in-class KHK inhibitor, PF-06835919 (8), currently in phase 2 clinical trials. The discovery of 8 was built upon our originally reported, fragment-derived lead 1 and the recognition of an alternative, rotated binding mode upon changing the ribose-pocket binding moiety from a pyrrolidinyl to an azetidinyl ring system. This new binding mode enabled efficient exploration of the vector directed at the Arg-108 residue, leading to the identification of highly potent 3-azabicyclo[3.1.0]hexane acetic acid-based KHK inhibitors by combined use of parallel medicinal chemistry and structure-based drug design.

  DOI：

  10.1021/acs.jmedchem.0c00944
• 作为产物：
  描述：

  exo-N-benzyl-3-azabicyclo[3.1.0]hexane-6-methanol 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 2.75h， 以703 g的产率得到[(1R,5S,6r)-3-benzyl-3-azabicyclo[3.1.0]hex-6-yl]methanol hydrochloride
  参考文献：
  名称：

  Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose

  摘要：

  Increased fructose consumption and its subsequent metabolism have been implicated in metabolic disorders such as nonalcoholic fatty liver disease and steatohepatitis (NAFLD/NASH) and insulin resistance. Ketohexokinase (KHK) converts fructose to fructose-1-phosphate (F1P) in the first step of the metabolic cascade. Herein we report the discovery of a first-in-class KHK inhibitor, PF-06835919 (8), currently in phase 2 clinical trials. The discovery of 8 was built upon our originally reported, fragment-derived lead 1 and the recognition of an alternative, rotated binding mode upon changing the ribose-pocket binding moiety from a pyrrolidinyl to an azetidinyl ring system. This new binding mode enabled efficient exploration of the vector directed at the Arg-108 residue, leading to the identification of highly potent 3-azabicyclo[3.1.0]hexane acetic acid-based KHK inhibitors by combined use of parallel medicinal chemistry and structure-based drug design.

  DOI：

  10.1021/acs.jmedchem.0c00944

文献信息

• [EN] NITROGEN-CONTAINING HETEROCYCLIC COMPOUND<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE CONTENANT DE L'AZOTE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013018929A1

  公开（公告）日：2013-02-07

  The present invention provides a novel compound having a superior activity as an ERR-α modulator and useful as an agent for the prophylaxis or treatment of ERR-α associated diseases. The present invention relates to a compound represented by the formula (1) wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种新型的化合物，作为一种ERR-α调节剂具有优越的活性，并可作为预防或治疗与ERR-α相关疾病的药物。本发明涉及一种由公式(1)表示的化合物，其中每个符号如说明书中所定义，或其盐。
• SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS
  申请人：Pfizer Inc.

  公开号：US20170183328A1

  公开（公告）日：2017-06-29

  Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

  本文提供了替代3-氮杂双环[3.1.0]己烷作为酮己糖激酶抑制剂，制备该类化合物的方法，以及包括向需要的哺乳动物施用该类化合物的方法。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
  申请人：MATSUMOTO Shigemitsu

  公开号：US20130072467A1

  公开（公告）日：2013-03-21

  The present invention provides a novel compound having a superior activity as an ERR-α modulator and useful as an agent for the prophylaxis or treatment of ERR-α associated diseases. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种新型化合物，作为ERR-α调节剂具有卓越的活性，可用作预防或治疗ERR-α相关疾病的药剂。本发明涉及一种由式所表示的化合物，其中每个符号如规范中所定义，或其盐。
• Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
  申请人：Pfizer Inc.

  公开号：US10174007B2

  公开（公告）日：2019-01-08

  Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

  本文提供了作为酮六磷酸酶抑制剂的取代 3-氮杂双环[3.1.0]己烷、制造所述化合物的工艺，以及将所述化合物施用给需要的哺乳动物的方法。
• US8772277B2
  申请人：——

  公开号：US8772277B2

  公开（公告）日：2014-07-08